Cellular Biomedicine Group
A-Stromal™ – The first certified product of its kind for adipose stromal cell purification in China
ProCeller – Exclusive China license for professional-grade adipose cell processing platform
(PublicWire.com Press Release) — PALO ALTO, Calif., Oct. 30, 2013 /PRNewswire/ — Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal™ adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These two products, when used together, allow for safe and contaminant-free isolation of one million Vascular Stromal Cells per 1 mL of adipose tissue in as little as sixty minutes. The potential clients for both products are cosmetic clinics, research institutions, sports medicine departments and veterinarian clinics.
The A-Stromal™ kit was developed completely in-house by Cellular Biomedicine Group, Inc. and is covered by two China patents. The China Food and Drug Administration (CFDA) approved this kit as a medical device and it is the first certified product of its kind in China. It contains all critical reagents and material to purify Vascular Stromal Cells (VSC) or Stromal Vascular Fraction (SVF) from adipose (fat) tissue and includes detailed instructions for use and hands-on training.
Dr. William Cao, CEO of Cellular Biomedicine Group, Inc., explained, “The proprietary protocols of the A-Stromal™ kit provide a high concentration of VSC, averaging one million VSC cells per 1 mL of adipose tissue, with greater than 90% cell viability. This allows the doctor to extract a very small amount of adipose tissue from the patient in order to isolate enough VSC required for a therapeutic or cosmetic procedure.”
The A-Stromal™ kits will be manufactured in Cellular Biomedicine Group’s cGMP-certified facility in Wuxi, China, which has been approved by the CFDA as a manufacturing facility for Medical Devices and is accredited ISO (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS.
Cellular Biomedicine Group HK, Ltd. (a subsidiary of Cellular Biomedicine Group, Inc.) has signed an exclusive license for the China and Hong Kong market with Dr. Hsu-Wei Fang, whose team holds the China patent and Taiwan patent for ProCeller, which is CE-marked. Dr. Fang is a Professor of the Department of Chemical Engineering and Biotechnology of National Taipei University of Technology (Taipei Tech) and brought ProCeller to the Taiwan market over two years ago.
ProCeller is an integrated, all-in-one computerized platform that offers a miniature cleanroom environment to isolate cells. The single piece of equipment is composed of a temperature controlled orbital shaker, integrated vacuum system, integrated centrifuge and HEPA filtered, self-sterilizing environment. It is a user-friendly interface with step-by-step procedures displayed on an LED screen.
“The advantage of the ProCeller equipment,” stated Dr. Fang, “is that normally a hospital or clinic would have to dedicate a significant amount of space within the clinic and purchase several pieces of costly equipment and raw materials in order to build their own cleanroom facility to process cells. The ProCeller machine is one integrated piece of equipment that takes up a relatively small amount of space and requires minimal training.”
ProCeller has been designed to meet the demands of many clinical and research applications, including isolation of VSC and SVF, purifying fat for lipotransfer in cosmetic surgery, isolating peripheral blood monocytes for immunological study, and separating platelet-rich plasma (PRP) for regenerative medicine use.
Dr. Cao commented, “We are proud to present ProCeller and A-Stromal™ kit as the first integrated system for fat cell processing to the Greater China market.”
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
News available on PublicWire.com